Please assess the completion status of the following clinical trial:

Trial Title: Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Previously untreated AML and high-risk MDS ( \> 10% blasts, or International Prognostic Scoring System (IPSS) intermediate-2). Prior therapy with hydroxyurea, single agent chemotherapy (e.g. decitabine), hematopoietic growth factors, biological or targeted therapies are allowed.~* Age \> 60 years.~* Eastern Cooperative Oncology Group (ECOG) performance status \</= 2.~* Sign a written informed consent form.~* Adequate liver function (total bilirubin \< 2mg/dL,serum glutamic pyruvic transaminase (SGPT) or Serum glutamic oxaloacetic transaminase (SGOT) \< x 4 upper limit of normal (ULN)) and renal function (serum creatinine \< 2mg/dL).~Exclusion Criteria:~* Patients with \>= New York Heart Association (NYHA) grade 3 heart disease as assessed by history and/or physical examination.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clofarabine (Type: ACTIVE_COMPARATOR): Clofarabine intravenous (IV) 30 mg/m\^2 daily times 5 days
- Clofarabine Plus Ara-C (Type: ACTIVE_COMPARATOR): Clofarabine IV 30 mg/m\^2 daily times 5 days + Ara-C 20 mg/m\^2 subcutaneously daily times 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).